Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.
Pathology is pivotal in the diagnostic process of many diseases such as cancer. For more than 100 years, pathologists have been using the optical microscope for tissue examination. The field of pathology is now challenged by the world’s shortage of pathologists, and the growing requirements for efficiency and consistent quality.
A revolution in the field
Recent progress in artificial intelligence, imaging, and high-performance computing has unlocked a revolution in the field: AI-powered Computational Pathology. Patholyt will bring research algorithms into clinical practice to both speed up and improve the quality of pathology diagnostics.
Patholyt aims to democratize the access to high quality pathology diagnostics around the world; and believes that at critical moments the chances of cancer patients can be improved through computational pathology. Patholyt’s AI-powered solutions will be integrated into standard digital pathology workflows, providing assistance to pathologists with a seamless experience.
Diagnostics & life sciences support
Patholyt’s products will focus on clinical diagnostic support for complex diseases such as prostate and breast cancer. The company will also provide solutions for biotech, pharma and diagnostics companies.
Patholyt originates from the group of Jeroen van der Laak, head of the Computational Pathology Group from Radboud University Medical Center (Radboudumc). The group is world-renowned for pioneering AI for large-scale whole-slide image analysis with high-ranking journal publications (e.g., automated grading of prostate cancer), the CAMELYON and PANDA challenges for breast and prostate cancer, and the IMI BIGPICTURE project. Patholyt’s management team consists of Patrick de Boer, Jeroen van der Laak, David Tellez and Wouter Bulten. Katrien Grünberg, Geert Litjens and Francesco Ciompi are members of the advisory board.
Related news items
Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm4 April 2022
Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides.read more
LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics7 February 2022
Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor.read more
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
Survey of patients to address knee pain from removed meniscus19 November 2021
Patients with persistent knee pain after meniscus removal can participate at three locations in the Netherlands in the AIR2 study by ATRO Medical, a spin-off of the Radboudumc and DSM.read more
Large AI project receives over €95 million for ten years of public-private research23 September 2021
The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs.read more
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more